Did you know that...

Children on dialysis have just 20 years of remaining life expectancy. Those lucky enough to receive a transplanted organ on average die 10-15 years younger than the general population.

 

Six cardiovascular risk factors recommended by the Kidney Disease Outcomes Quality Initiative were assessed only 57 % of the time by physicians at the 8 hospitals in this study.

 
 Hooper, D. K., Williams, J. C., Carle, A. C., Amaral, S., Chand, D. H., Ferris, M. E., & ... Patel, U. D. (2013). The quality of cardiovascular disease care for adolescents with kidney disease: a Midwest Pediatric Nephrology Consortium study.  Pediatric Nephrology , (6), 939. doi:10.1007/s00467-013-2419-6

Hooper, D. K., Williams, J. C., Carle, A. C., Amaral, S., Chand, D. H., Ferris, M. E., & ... Patel, U. D. (2013). The quality of cardiovascular disease care for adolescents with kidney disease: a Midwest Pediatric Nephrology Consortium study. Pediatric Nephrology, (6), 939. doi:10.1007/s00467-013-2419-6


 

IROC harnesses the inherent motivation and expertise of all stakeholders to improve care, spawn innovation and conduct research that improves health and outcomes for children with kidney disease.

 
 
Photo by shutterbugger/iStock / Getty Images

Connecting the top minds in the field to the patients they care for, IROC has the potential to positively impact the lives of millions of kids around the world. 


The greatest obstacle to improving long-term outcomes for children with kidney disease is not the lack of available therapies, but rather the lack of effective healthcare delivery systems that implement existing therapies reliably in clinical practice.
— David K. Hooper MD, MS, Medical Director of Kidney Transplantation, Cincinnati Children's Hospital and Director, IROC

Improvement is Possible

An IROC Hospital's kidney transplant team used quality improvement methods to redesign their clinic processes and medical record systems to proactively support physicians in performance of recommended care.  

By developing standardized treatment protocols, measuring and reporting care and outcomes, and supporting clinical decision-making through planned medical visits, the team improved cholesterol control from 63% of patients to over 90% within three years without any new medications. 

Hooper, D. K., Kirby, C. L., Margolis, P. A., & Goebel, J. (2013). Reliable individualized monitoring improves cholesterol control in kidney transplant recipients. Pediatrics, (4), 1271.